RASSF1 (Ras Association Domain Family Member 1)

Pre-analytical confounders (blood collection tubes, hemolysis, storage conditions), platform-dependent analytical variation, lack of external quality assessment programs, and scarcity of demonstrations of clinical utility in prospective biomarker-directed research are critical translational barriers. Such standardized handling of specimens, commutable reference materials, and reporting of the characteristics of analytical performance would be clearly linked to effective clinical use in accordance with the requirements of laboratory medicine.

Combining Shox2 and Rassf1a methylation with EGFR mutations demonstrated enhanced discriminative capacity for early-stage lesions. Our study demonstrated that comprehensive analysis of methylation and gene mutations could provide a novel clinical strategy for molecular subtyping and precision medicine in LUAD.

The most frequent methylation related microRNA was miR-296, followed by miR-193 and miR-137. This study for the first time elucidated the scientometric characteristics of all the publications on methylation modification in oral carcinogenesis, and would provide new insights for researchers to comprehend the methylation specific gene profile related OPMD/OSCC.

While not definitive, this evidence may potentially support the transcriptomic and splicing findings. SRPK1 inhibition may remodel the cervical cancer transcriptome in an HPV-linked manner, with SiHa cells exhibiting changes consistent with suppression of oncogenic signaling, whereas C33A cells adapt through translational and metabolic reprogramming.

Cytological examination combined with methylation detection can greatly improve the diagnosis rate of malignant ascites. The methylation status of SHOX2 and SEPTIN9 genes is significantly correlated with the prognosis of patients with ascites.

Bilberry pomace shows multitarget anticancer activity across BC models; translational studies should confirm mechanisms, refine dosing, and explore biomarker-guided use.

Liquid biopsy demonstrates strong diagnostic and prognostic potential across GU cancers. While bladder and prostate cancer assays are most advanced, emerging evidence in UTUC and kidney cancer is encouraging. Prospective, longitudinal validation remains essential before widespread clinical adoption.

This regulatory interaction was confirmed through DNA methylation sequencing, methylation-specific PCR, and chromatin immunoprecipitation assays. These findings highlight the pivotal role of DNMT1-driven RASSF1A methylation in facilitating breast cancer metastasis to the brain, and suggest that targeting DNMT1 may represent a promising therapeutic approach for managing metastatic breast cancer.

The cooperative GOG 281/LOGS trial showed that trametinib, an MEK inhibitor (MEKi), was significantly more effective than standard-of-care options (including chemotherapy or hormonal therapy) in increasing progression-free survival (median PFS 13.0 months vs. 7.2 months; hazard ratio 0.48, p < 0.001)...Genomic and multi-omic profiling have revealed actionable vulnerabilities and precision oncology approaches. The advent of biomarker-directed trials, molecular subtyping incorporation, and innovative computational strategies is likely to gradually ameliorate therapy selection and, thereby, finally improve long-term outcomes for patients with this complex disease.

Building on this sequestration-and-release mechanism, we identify microtubule-binding C1 domains in additional signaling proteins, including other guanine nucleotide exchange factors (GEFs), kinases, a GTPase-activating protein (GAP), and a tumor suppressor, and show that microtubule-mediated regulation via C1 domains is conserved in the Ras association domain-containing protein 1A (RASSF1A). Our findings establish a structural framework for understanding how microtubules can function as spatiotemporal signal sensors, integrating and processing diverse signaling pathways to control important cellular processes.

Moreover, integrating multi‑omics data with artificial intelligence and machine learning may further improve early detection and personalized treatment strategies. Overall, the development and clinical implementation of these biomarkers represent a transformative step toward precision medicine in prostate cancer, enabling earlier diagnosis, optimized therapy selection and improved patient outcomes.

This study provides compelling evidence that the combination of RASSF1A/TSPYL5 methylation and AFP protein is a promising biomarker panel for the early detection of HCC. The ARTHCC model demonstrates remarkable sensitivity and specificity, outperforming AFP.